Astellas Pharma Inc 4503
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA
-
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
-
Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer
-
Merck, Pfizer Report Positive Results From Combined Bladder-Cancer Trial
-
Vir Biotechnology, Astellas in $335 Million Licensing Deal for Prostate Cancer Treatment
-
'Women deserve an apology': For menopause, hormone therapy is now considered safe - just in time for aging millennials
-
Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study
-
FDA Approves Merck's Keytruda with Padcev to Treat Bladder Cancer — Update
Trading Information
- Previous Close Price
- ¥2,327.50
- Day Range
- ¥2,334.00–2,369.50
- 52-Week Range
- ¥1,557.50–2,717.00
- Bid/Ask
- ¥2,355.50 / ¥2,359.00
- Shares Outstanding
- 1.79B
- Market Cap
- ¥4.23T
- Volume/Avg
- 5M / 7M
Key Statistics
- Price/Earnings (Normalized)
- 14.52
- Price/Sales
- 1.98
- Dividend Yield (Trailing)
- 3.31%
- Dividend Yield (Forward)
- 3.39%
- Total Yield
- 3.33%
Company Profile
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 14,099
- Website
- https://www.astellas.com
Valuation
|
Metric
|
4503
|
|---|---|
Price/Earnings (Normalized) | 14.52 |
Price/Book Value | 2.17 |
Price/Sales | 1.98 |
Price/Cash Flow | 6.61 |
Price/Earnings
4503
Financial Strength
|
Metric
|
4503
|
|---|---|
Quick Ratio | 0.86 |
Current Ratio | 1.17 |
Interest Coverage | 27.19 |
Quick Ratio
4503
Profitability
|
Metric
|
4503
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
4503
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#!<FdZ> | LOCK|$$ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|#PBDgL? | LOCK|Z<B | $627B | |||
| AbbVie Inc
ABBV
| LOCK|?Bf?#Y< | LOCK|Qw | $441B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?BZy&&^Z | LOCK|$# | $348B | |||
| Merck & Co Inc
MRK
| LOCK|YYg&>S# | LOCK|X> | $335B | |||
| Novartis AG ADR
NVS
| LOCK|&Fh!Qg$ | LOCK|%cQ | $286B | |||
| AstraZeneca PLC
AZN
| LOCK|>fBx?V@ | LOCK|%cj | $240B | |||
| Amgen Inc
AMGN
| LOCK|XK%NNHH | LOCK|Jy | $224B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!v@W>p | LOCK|xLP | $201B | |||
| Gilead Sciences Inc
GILD
| LOCK|s$RKYX | LOCK|@! | $172B |
United States